Research
Hormonal
GLP-1 receptor agonists (GLP-1RA) such as semaglutide and liraglutide produce significant weight loss (≥10%) and cardiovascular benefits in adults with obesity.
GLP-1 receptor agonists like semaglutide are highly effective for weight loss, often achieving 10% or more body weight reduction, and also provide cardiovascular benefits. These medications are available in both injectable and oral forms, offering flexibility for long-term management of obesity.
StrongSupportsVERY_HIGH confidence
The therapeutic landscape for GPCR as targets of anti-obesity medications has undergone significant changes with the approval of semaglutide, the first peptide glucagon like peptide 1 receptor agonist (GLP-1RA) achieving double digit weight loss (≥10%) and cardiovascular benefits.
Why this rating
The paper cites multiple large-scale clinical trials (SELECT trial, STEP 8) and FDA approvals.
Source
G protein-coupled receptors and obesity
Alessandro Pocai · Frontiers in Endocrinology · 2023
narrative_reviewCited 9×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →